Hamed Yasavoli Sharahi, PhD - De Perrot Research Lab

Marc de Perrot

Update on pleural epithelioid mesothelioma: New insights for diagnosis and patient management April 10, 2026
Diffuse Mesothelioma is typically diagnosed through histopathologic evaluation. Recent advances in therapeutic strategies have heightened the importance of accurate diagnosis and subtyping. In addition to the three well-established histological subtypes of mesothelioma (epithelioid, biphasic and sarcomatoid), the 2021 WHO classification of diffuse pleural mesothelioma [DPM] emphasizes the importance of subtyping patterns and cytological features to […]
Pulmonary Artery Sarcoma Study: A Multi-Center ESTS Working Group Evaluating Diagnosis, Treatment, and Outcomes March 28, 2026
CONCLUSIONS: This study represents the largest reported PAS cohort to date and underscores the diagnostic challenges and poor prognosis associated with this disease. Our findings offer evidence that multimodal treatment provides significant prognostic benefits. However, further prospective studies are warranted to establish standardized diagnostic and therapeutic protocols.
Distinct endothelial cells in chronic thromboembolic pulmonary hypertension March 3, 2026
Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening condition characterized by unresolved thrombi obstructing the pulmonary arteries. Endothelial cells (ECs) are essential regulators of thrombosis and thrombus resolution, yet their molecular phenotypes in CTEPH are incompletely understood. Using single-cell RNA sequencing of CTEPH surgical specimens and control ECs from the Human Lung Cell Atlas, we […]
Reperfusion strategies while on ECMO for catastrophic PE: Keep fishing or cut bait? February 25, 2026
No abstract
Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay February 23, 2026
CONCLUSION: Here, we demonstrate the clinical feasibility of plasma ctDNA to inform treatment decision-making in stage I NSCLC.
Utility of Computed Tomography-Based Intraoperative Surgical Margin Evaluation in Wedge-Resected Lung Specimens February 9, 2026
CONCLUSIONS: CT-based margin evaluation method can provide an intraoperative timely and more reliable estimate of the pathMargin compared to surgeon's estimates and could be a novel approach to ensure more sufficient surgical margins during wedge resection.
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies February 4, 2026
Neoadjuvant chemoimmunotherapy (chemo-IO) has fundamentally reshaped the treatment paradigm for resectable non-small cell lung cancer (NSCLC), challenging long-held surgical boundaries and redefining what constitutes "resectable" disease. Trials such as CheckMate-816, KEYNOTE-671, and AEGEAN have demonstrated that integrating immune checkpoint blockade with chemotherapy yields unprecedented rates of pathological response and event-free survival, positioning chemo-IO as the […]
Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement January 18, 2026
No abstract
Clinical implications of frailty in hospitalized patients with pulmonary arterial hypertension December 24, 2025
ObjectivesFrailty is associated with increased morbidity and mortality in chronic lung disease, but its prognosis has not been evaluated in pulmonary arterial hypertension (PAH). This study aimed to assess: (1) impact of frailty on hospital length of stay (LOS) and health-care utilization in PAH; (2) association of frailty with 1-year post-discharge outcomes.MethodsRetrospective, single-centered cohort study […]
Considerations for Endpoints in Lung Transplant Clinical Trials: An ISHLT Consensus Statement December 16, 2025
Clinical trials in lung transplantation have been hindered by a lack of clarity on the formulation and significance of endpoints for evaluating therapeutic efficacy. To address this challenge, a multidisciplinary working group from the International Society for Heart and Lung Transplantation developed consensus recommendations on endpoints beyond mortality. These endpoints include primary graft dysfunction (PGD), […]
Reply to the Letter to the Editor: Rethinking the clinical utility of machine learning for CTEPH severity November 28, 2025
No abstract
Endothelin-1 overexpression in pulmonary endarterectomy specimens of CTEPH patients is associated with pulmonary hypertension development September 27, 2025
CONCLUSIONS: ET-1 release from thromboembolic material of CTEPH patients could be an important mechanism leading to PH. Hence, ET-1 receptor antagonists should continue to be investigated as a potential therapeutic agent in CTEPH patients.
The Tempest Surrounding Lung Transplant for Lung Cancer, With Lung Cancer, or With Isolated Lung Metastases September 12, 2025
Lung transplantation for cancer is controversial. The hesitancy has largely been driven by historical outcomes. However, early-stage lung cancer does not significantly affect the outcome of lung transplant for other end-stage lung diseases. We have also made more donor lungs available and hence can consider transplanting patients where the only curative option is to resect […]
One thousand cases of ex vivo lung perfusion for lung transplantation: A single-center experience September 5, 2025
CONCLUSIONS: Ex vivo lung perfusion has emerged as a safe, effective, and scalable platform for donor lung evaluation. Its integration into clinical practice has supported broader donor organ use and excellent patient outcomes, while laying the foundation for continued innovation in lung transplantation.
Utility of machine learning for predicting severe chronic thromboembolic pulmonary hypertension based on CT metrics in a surgical cohort August 23, 2025
CONCLUSIONS: While measures of PE burden had little bearing on PH severity independently, the RV/LV ratio, extent of disease in various segments, total webs observed, and patient demographics improved performance of machine learning models in identifying severe PH.

Partners: Latner Labs

University of Toronto

University Health Network